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Congenital afibrinogenemia is a rare autosomal recessive coagulation disorder characterised by hemorrhagic manifestations of variable
entity and by severe plasma fibrinogen deficiency. Among the 31 afibrinogenemia-causing mutations so far reported, only 2 are missense
mutations and both are located in the fibrinogen Bh-chain gene.
Direct sequencing of the fibrinogen gene cluster in two afibrinogenemic Iranian siblings revealed a novel homozygous T>G transversion
in exon 8 (nucleotide position 8025) of the fibrinogen Bh-chain gene. The resulting W437G missense mutation involves a highly conserved
amino acid residue, located in the C-terminal globular D domain. The role of the W437G amino acid substitution on fibrinogen synthesis,
folding, and secretion was assessed by in vitro expression experiments in COS-1 cells, followed by qualitative and quantitative analyses of
intracellular and secreted mutant fibrinogen. Results of both pulse-chase experiments and enzyme-linked immunosorbent assays
demonstrated intracellular retention of the mutant W437G fibrinogen and marked reduction of its secretion.
These data, besides elucidating the pathogenetic role of the W437G mutation in afibrinogenemia, underline the importance of the Bh-
chain D domain in fibrinogen folding and secretion.
D 2003 Elsevier B.V. All rights reserved.Keywords: Congenital afibrinogenemia; Fibrinogen Bh-chain; Missense mutation; Protein in vitro expression1. Introduction
First described in 1920, congenital afibrinogenemia
(Mendelian Inheritance in Man #202400) is a rare coagula-
tion disorder, transmitted as an autosomal recessive trait,
which is therefore clinically expressed only in genetically
homozygous or in compound heterozygous patients. Con-
genital afibrinogenemia is characterised by spontaneous,
post-partum, and post-surgical hemorrhages of variable
entity and by a severe fibrinogen deficiency both in plasma
and in platelets [1].
Fibrinogen is an acute phase class II protein [2] and its
proteolytic conversion to fibrin represents the final step of
the hemostatic process [3]. The main source of fibrinogen is0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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tively express fibrinogen at high levels. Transcription of the
three fibrinogen Aa-, Bh-, and g-chain genes, clustered in a
50-kb region on chromosome 4q28 [4], is coordinated and
up-regulated following inflammation or tissue injury. Fi-
brinogen is a homodimer with each half-molecule composed
of a copy of the three different fibrinogen chains (Aa, Bh,
and g), which are assembled in a complex step-wise manner
(for review, see Ref. [5]). The hexameric molecule is
stabilised by an extensive network of 29 disulfide bonds
and its complete assembly is a prerequisite for the secretion
of the 340-kDa glycoprotein. The 450-A˚ elongated trinod-
ular fibrinogen structure is composed of two distal globular
D domains (composed of N- and C-terminal small subdo-
mains and a central domain) joined to a central E domain by
coiled-coil regions [6].
Since 1999, 31 mutations responsible for the afibrinoge-
nemic phenotype have been described in the fibrinogen gene
cluster [7–13]. Among afibrinogenemia-causing gene alter-
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and 11 nonsense mutations), most have been found in the
fibrinogen Aa-chain gene and are predicted to cause C-
terminal truncations of variable length of the corresponding
polypeptides. The only two missense mutations, both located
in the fibrinogen Bh-chain gene, were demonstrated to impair
fibrinogen secretion [14], supporting the concept that spon-
taneous mutations, in particular missense, are a useful tool for
studying the structural role of specific amino acids in the
complex mechanism of fibrinogen assembly and secretion.
In this paper, the identification and the characterisation of
a novel missense mutation (W437G) located in the fibrin-
ogen Bh-chain gene in two afibrinogenemic Iranian siblings
are reported. The W437G amino acid substitution is caused
by a homozygous T to G transversion in exon 8 of the Bh-
chain gene at nucleotide position 8025. The pathogenetic
role of the W437G mutation was investigated by expression
experiments of the mutant fibrinogen molecule in COS-1
cells. The results obtained demonstrated that the W437G
mutation impairs fibrinogen secretion and causes intracel-
lular retention of the mutant molecule.2. Materials and methods
This study was approved by the Institutional Review
Board of the University of Milan. Citrate-anticoagulated
blood samples were withdrawn from all individuals after
acquiring an appropriate informed consent.
2.1. Materials
pRSV-Neo-Aa, pRSV-Neo-Bh, and pRSV-Neo-g plas-
mids [15,16], containing the full-length cDNAs coding for
the three fibrinogen chains, were kindly provided by Dr.
C.M. Redman (Lindsley F. Kimball Research Institute, New
York Blood Center, New York, NY, USA). Rabbit poly-
clonal antibodies to human fibrinogen were from DAKO
(Copenhagen, Denmark). Oligonucleotides were purchased
from Invitrogen (Carlsbad, CA, USA).
2.2. Coagulation tests
Plasma functional and antigen fibrinogen levels were
measured by an assay based on fibrin polymerisation time
(Laboratoire Stago, Asnie`res, France) and by an enzyme-
linked immunosorbent assay (ELISA) [17], respectively.
The sensitivities of the functional and of the immunologic
assays were 5 and 0.0005 mg/dl, respectively (normal
values for both tests ranged between 160 and 400 mg/dl).
2.3. DNA sequence analysis
Genomic DNAwas extracted from whole blood using the
PUREGENE Kit (Gentra Systems, Minneapolis, MN, USA),
following the manufacturer’s instructions. PCR amplifica-tions were performed on genomic DNA under standard
conditions in a PTC-100 thermal cycler (MJ-Research,
Watertown, MA, USA). Primer sequences (provided on
request) were designed on the basis of known sequences of
the three fibrinogen genes and intergenic regions (GenBank
accession numbers M64982, M64983, M10014, U36478,
and AF229198). The amplified fragments were purified by
ammonium acetate precipitation and directly sequenced on
both strands using the BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA). Sequenc-
ing primers were the same as in amplification reactions
except those used for the long exon 5 of the Aa-chain gene,
which was sequenced using additional internal primers.
Sequencing reactions were analysed on an ABI-3100 multi-
capillary automated DNA sequencer (Applied Biosystems).
Factura and Sequence navigator software (Applied Biosys-
tems) were used for mutation detection.
2.4. Site-directed mutagenesis
pRSV-Neo-Bh plasmid was used as template for site-
directed mutagenesis using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA), accord-
ing to the protocol provided with the kit. The mutagenic
primer couple 5V-GATGATGGTGTAGTAGGGATGAATT-
GGAAG-3Vand 5V-CTTCCAATTCATCCCTACTACACCA-
TCATC-3V (underlined letters indicate the mismatch),
corresponding to nucleotide positions 8010–8039 (Gen-
Bank accession number M64983), was used. The resulting
mutant plasmid (pRSV-Neo-Bh-W437G) was checked by
sequencing.
2.5. Cell cultures, transfections, and metabolic labelling
The human hepatoma HepG2 cell line was cultured in
Dulbecco’s modified Eagle’s Medium (DMEM) and Ham’s
F12 media (1:1, vol/vol), supplemented with 10% fetal calf
serum. The African green monkey kidney COS-1 cell line
was maintained in DMEM containing 10% fetal calf serum.
Glutamine (1%) and antibiotics (100 IU/ml penicillin and
100 Ag/ml streptomycin) were added to both media. Cells
were grown at 37 jC in a humidified atmosphere of 5% CO2
and 95% air.
Semiconfluent COS-1 cells were co-transfected with
equimolar amounts of pRSV-Neo-Aa, pRSV-Neo-g, and
pRSV-Neo-Bh plasmids, the last one being either wild-type
or mutant. As negative control, COS-1 cells were also mock
transfected with the unrelated pUC18 plasmid. All plasmids
were extracted using the EndoFree Plasmid Maxi Kit
(Qiagen, Hilden, Germany). Cells were transfected using
the Lipofectamine 2000k reagent (Invitrogen), following
the manufacturer’s instructions.
For immunoprecipitation analyses, transfections were
performed in six-well plates. Thirty-six hours after trans-
fection, cells were washed twice with methionine- and
cysteine-free DMEM (ICN Biomedicals, High Wycombe,
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methionine- and cysteine-free DMEM supplemented with
200 ACi [35S]-labelled methionine and cysteine (Translable;
ICN Biomedicals), 10% dialysed fetal calf serum, 2 mM
L-glutamine, 2.5 mM CaCl2, 5 mg/ml bovine serum albumin,
and 0.1 mg/ml heparin. After 2 h labelling, cells were
washed twice with phosphate-buffered saline (PBS) and
chase was performed for various time-periods (0, 30, 60,
120, and 180 min) by adding 1 ml/well of DMEM supple-
mented with a 10-fold excess cold methionine and a 5-fold
excess cold cysteine, 10% fetal calf serum, 2 mM L-gluta-
mine, 2.5 mM CaCl2, 5 mg/ml bovine serum albumin, and
0.1 mg/ml heparin.
For ELISA measurements, transfections were performed
in 10-cm-diameter dishes. Sixteen hours after transfection,
cells were washed twice with PBS and cultured for addi-
tional 48 h in serum-free DMEM supplemented with 2 mM
L-glutamine, 2.5 mM CaCl2, 5 mg/ml bovine serum albu-
min, and 0.1 mg/ml heparin.
2.6. Immunoprecipitation and sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
Conditioned media were collected in pre-chilled tubes
containing a protease inhibitor mixture (Complete; Roche,
Basel, Switzerland), centrifuged to remove cell debris, and
stored at  80 jC. Preparation of cell lysates and immuno-Fig. 1. Pedigree of the analysed afibrinogenemic family and electropherogram
Measurements of functional and immunoreactive plasma fibrinogen (mg/dl) are r
indicated by a double line; the arrow indicates the proband. Half-filled and filled s
not done. (B) Electropherograms of the region surrounding the identified mutation
(I2), a homozygous mutant (II2), and a control individual (wild type). The posit
number M64983) is indicated by an arrow; the wild-type and the correspondingprecipitations were performed as previously described [14],
except for the use of protein A (Sigma Chemical, St. Louis,
MO, USA) instead of protein G. The immunoprecipitated
proteins were released from protein A by boiling for 5 min
in SDS-PAGE Laemmli loading buffer (without reducing
reagent) and were resolved by non-reducing 4% SDS-
PAGE. Gels were dried under vacuum at 80 jC for 1 h.
Labelled proteins were visualised by exposing gels over-
night to a storage phosphor screen (Amersham Pharmacia
Biotech, Uppsala, Sweden) and analysed using a Typhoon
9200 phosphor imager and the ImageQuant software (Amer-
sham Pharmacia Biotech).
2.7. Fibrinogen antigen measurement in conditioned media
and cell lysates
Fibrinogen antigen levels were evaluated in conditioned
media and cell lysates by the same ELISA assay used to
measure fibrinogen in plasma. Conditioned media were
collected in pre-chilled tubes containing a protease inhibitor
cocktail (Complete; Roche) and centrifuged to remove cell
debris. An aliquot (8 ml) from each supernatant was 40-fold
concentrated by Centricon Plus-20 centrifugal filters (Milli-
pore, Bedford, MA, USA). Cell lysates were prepared by
washing cells twice with pre-chilled PBS and by lysing cells
for 1 h on ice in a lysis buffer (1 PBS, 1% Triton X-100,
and the protease inhibitor cocktail). Lysates were centri-s showing the identified mutation. (A) Pedigree of the Iranian family.
eported in this order below each symbol. The consanguineous marriage is
ymbols denote heterozygous and homozygous individuals, respectively. Nd:
in the Bh-chain gene. Top to bottom: electropherograms of a heterozygous
ion of the T>G transversion (numbered according to GenBank, accession
mutant codons are underlined. K denotes G or T nucleotides.
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were stored at  80 jC.3. Results
3.1. Family clinical history
The analysed proband is a 12-year-old Iranian boy born
from consanguineous asymptomatic parents. Diagnosis of
afibrinogenemia was made at birth after prolonged umbilical
cord bleeding and laboratory measurements that revealed
unmeasurable functional fibrinogen level ( < 5 mg/dl) and an
extremely low value of immunoreactive fibrinogen (0.062
mg/dl) in plasma (Fig. 1A). Subsequently, symptoms were
bleeding after dental extraction, spontaneous nose and
mouth bleedings, and recurrent hemarthroses and hemato-
mas. The 18-year-old proband’s sister suffered from a
similar hemorrhagic diathesis at birth (umbilical cord bleed-
ing) and during childhood and puberty (hemarthroses and
muscle hematomas); recently performed laboratory coagu-
lation test revealed extremely reduced (1.8 mg/dl) antigen
fibrinogen concentration in plasma. Both parents showed
plasma antigen fibrinogen levels close to the lower normal
limit (157 and 186 mg/dl for the mother and the father,
respectively) (Fig. 1A).Fig. 2. Position of the W437G mutation in the fibrinogen Bh-chain structure. (A)
several vertebrates. Protein sequences were obtained from Swiss-Prot database (htt
Q91589 (frog), Q02020 (chicken), P02676 (bovine), P14480 (rat), and P02675 (h
position of the W437G mutation. Conserved amino acids are boxed and identical r
shown as arrows below the alignment and refer to the human protein. Regions
fibrinogen Bh-chain C-terminal region showing the position of the W437G mut
software [18] and the crystal structure coordinates of human fibrinogen D fragme
depicted and indicated by an arrow; the N-terminal (K148) and the C-terminal (Q
also indicated.3.2. Identification of the W437G mutation
To identify the genetic defect responsible for the ob-
served afibrinogenemic phenotype, PCR fragments, cover-
ing the whole coding regions, all intron–exon junctions, and
about 300 bp of the promoter regions of the three fibrinogen
genes, were obtained from proband’s genomic DNA. Direct
sequencing of amplified fragments was performed on both
strands. A novel homozygous base-pair substitution (T to
G), located in exon 8 of the fibrinogen Bh-chain gene at
nucleotide position 8025 (numbering according to GenBank
accession number M64983), was the only identified nucle-
otide variation (Fig. 1B). This transversion was detected in
the homozygous state also in the afibrinogenemic proband’s
sister and in the heterozygous state in both parents (Fig. 1B).
This mutation was absent in a control group of 50 unrelated
Iranian individuals.
At the protein level, the resulting missense mutation,
from tryptophan (TGG) to glycine (GGG) at codon 437 of
the fibrinogen Bh-chain (numbering omitting the signal
peptide), involved a highly conserved amino acid residue
(Fig. 2A). W437 is located in a h-strand participating in the
formation of an antiparallel h-sheet, which is part of the C-
terminal globular D domain of the Bh-chain [6] (Fig. 2B).
Consequently, the W437G mutation may lead to a misfolded
protein, not competent for secretion.
ysica Acta 1639 (2003) 87–94Multiple alignment of the C-terminal regions of fibrinogen Bh-chains from
p://www.expasy.org/sprot/) under the accession numbers P02678 (lamprey),
uman). Protein numbering omits the signal peptide. The arrow indicates the
esidues are shaded in grey. The regions of secondary structure (h-strand) are
of random coil are indicated by straight lines. (B) Ribbon structure of the
ation. The ribbon diagram was produced using the Swiss-Pdb Viewer 3.7
nt deposited in Protein Data Bank (entry 1FZA) [6]. The W437 residue is
461) residues of the Bh-chain belonging to the crystallised D fragment are
Biophysica Acta 1639 (2003) 87–94 913.3. Pulse-chase analysis of wild-type and mutant
fibrinogen molecules
To investigate the effect of the W437G substitution on
fibrinogen synthesis, folding, stability, and secretion, ex-
pression experiments of the mutant fibrinogen molecule
were performed. To this purpose, an in vitro approach was
adopted. pRSV-Neo-Aa, pRSV-Neo-Bh, and pRSV-Neo-g
mammalian expression vectors were used. The identified
mutation was inserted into the pRSV-Neo-Bh plasmid by
site-directed mutagenesis, to produce the mutant pRSV-
Neo-Bh-W437G construct. Wild-type and mutant homozy-
gous phenotypes were mimicked by transiently co-trans-
fecting COS-1 cells (not expressing fibrinogen) with
equimolar mixtures of pRSV-Neo-Aa and pRSV-Neo-g
plasmids supplemented with pRSV-Neo-Bh or pRSV-Neo-
Bh-W437G at the same molar concentration. Untransfected
HepG2 cells (expressing fibrinogen) and mock-transfected
(pUC18) COS-1 cells were used as positive and negative
controls, respectively.
Following a 2-h pulse with [35S]-methionine and [35S]-
cysteine, chase was performed for various periods of time
(0, 30, 60, 120, and 180 min), by using an excess of the
corresponding unlabelled amino acids. At each time-point,
recombinant radiolabelled fibrinogen molecules were iso-
lated by immunoprecipitation from media and cell lysates.
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COS-1 cells transfected with equimolar mixtures of wild-type Aa- and g-chains, to
mock-transfected (pUC18) COS-1 cells represent the positive and negative control
for 2 h and subsequently chased for 0, 30, 60, 120, and 180 min as described in Ma
reducing conditions. The arrowhead indicates the 340-kDa hexameric fibrinogen m
(white bars) and mutant (grey bars) immunoprecipitated fibrinogen is shown on th
calculated by the ImageQuant software by integrating intensities of all the pixels
panels, each value was normalised using the intensity of the HepG2 fibrinogen bAnalysis of expressed hexameric fibrinogen molecules was
carried out by SDS-PAGE under non-reducing conditions.
As expected, the specific wild-type 340-kDa fibrinogen
band decreased in cell lysates (from 30 to 180 min of chase)
and increased in culture media at the corresponding ana-
lysed chase-periods (Fig. 3A and B, left). By contrast,
mutant fibrinogen was detected intracellularly up to 180
chase-minutes and it was undetectable in conditioned media
at the corresponding periods of chase, suggesting a normal
synthesis and intracellular assembly, associated with abnor-
mal intracellular accumulation and impaired secretion of the
mutant molecule (Fig. 3A and B, middle). These data were
confirmed by densitometric quantitation of fibrinogen bands
(Fig. 3A and B, right), which also revealed the presence of
similar amounts of intracellular hexameric fibrinogen at
time period 0 in cells expressing wild-type or BhW437G
molecules. Fibrinogen was also detected in cell extracts and
in culture media of HepG2 cells, whereas only a background
band, present in all samples, was detected in the negative
control (Fig. 3A and B, left and middle).
3.4. ELISA quantitation of wild-type and mutant
recombinant fibrinogens
To confirm the immunoprecipitation results, a quantita-
tive analysis, based on ELISA measurements, was per-oprecipitated proteins from cell lysates (A) and conditioned media (B) of
gether with wild-type or W437G Bh-chains. Untransfected HepG2 cells and
s, respectively. Cells were labelled with [35S]-methionine and [35S]-cysteine
terials and methods. Samples were separated on 4% SDS-PAGE under non-
olecule. A densitometric analysis of the bands corresponding to wild-type
e right. Bar graphs are expressed as arbitrary densitometry units ( y-axis), as
in the band excluding the background. To compare samples from different
and from the same panel.
Fig. 4. ELISA measurements of in vitro expressed wild-type and mutant
Bh-W437G fibrinogens. Wild-type or mutant fibrinogens were expressed in
COS-1 cells following transfection with equimolar mixtures of wild-type
Aa- and g-chains, together with wild-type or W437G Bh-chains.
Fibrinogen antigen levels were evaluated in cell lysates and conditioned
media by means of an ELISA assay (see Materials and methods).
Intracellular, secreted, and 40 -concentrated secreted fibrinogens (x-axis),
detected in wild-type (white bars) and in mutant (gray bars) samples, are
reported as milligrams per deciliter ( y-axis). Levels of mutant molecules are
also indicated above each bar as percentage of the corresponding wild-type
proteins, set equal to 100%.
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equimolar amounts of the expression plasmids, as for the
pulse-chase analysis. Forty-eight hours after transfection,
fibrinogen antigen levels were evaluated both in cell extracts
and in serum-free media. ELISA assays showed that intra-
cellular wild-type fibrinogen was about one-half that mea-
sured in the corresponding conditioned media (0.0014 vs.
0.0027 mg/dl, Fig. 4), while mutant immunoreactive fibrin-
ogen was approximately 6-fold more abundant in cell
extracts than in conditioned media (0.0025 vs. 0.0004 mg/
dl, Fig. 4). Since equal numbers of cells were co-transfected
and equal quantities of samples were analysed by the ELISA
test, comparison of these results revealed that in cell
extracts, mutant fibrinogen was 178.5% of the wild-type
(set as 100%), while in culture media, it represented only
14.8% (Fig. 4), confirming that the W437G mutation causes
intracellular retention and impaired secretion of fibrinogen
molecules. Since mutant fibrinogen levels in culture media
were slightly below the sensitivity limit of the ELISA assay,
fibrinogen antigen levels were also measured in conditioned
media after 40-fold concentration. The secreted mutant
molecule was found to be 0.008 mg/dl, only up to 9.5%
of the wild-type (Fig. 4), confirming the results obtained on
unconcentrated media.4. Discussion
Although many (more than 300) cases of congenital
afibrinogenemia have been described from a clinical point
of view, only a few (less than 20%) have had the causal
mutations identified. In this study, we report the identifica-tion of a novel genetic defect in an afibrinogenemic Iranian
proband and his sister, born from a consanguineous mar-
riage (Fig. 1A). As expected for autosomal recessive traits,
inbreeding is frequently observed among families with
afibrinogenemia [19].
Clinically, the two siblings had similar severe hemor-
rhagic manifestations (hemorrhages from the umbilical cord,
hemarthroses, and hematomas). Sequence analysis of all the
three fibrinogen genes revealed a novel T to G transversion
at position 8025 in exon 8 of the Bh-chain gene, present in
the homozygous state in both the proband and his affected
sister (Fig. 1B). Given the high variability in clinical
severity of this rare coagulation disorder, even in patients
carrying identical genetic defects [7], the occurrence of
similar symptoms in the two analysed siblings may be due
not only to the presence of the same mutation but also to the
sharing of a common genetic background.
The newly identified mutation changes the first nucleo-
tide of codon 437 and results in a missense mutation,
leading to a Trp!Gly substitution (W437G). Only two
missense mutations (L353R and G400D), both located in
the Bh-chain gene, have been so far described as responsi-
ble for afibrinogenemia [14]. The rarity of missense muta-
tions (about 9% of known afibrinogenemia-causing
alterations, including the W437G mutation) contrasts with
the general finding that they constitute more than one-half
of the mutations in human genetic diseases [20]. Similarly to
L353R and G400D mutations, the here reported W437G
substitution involves a highly conserved amino acid residue
located in the C-terminal globular D domain (comprising
residues 198–461) of the fibrinogen Bh-chain (Fig. 2A and
B). However, while both L353R and G400D mutations are
located in unstructured protein regions and impair fibrino-
gen secretion by introducing charged side chains in the
hydrophobic core of the Bh D domain [14], the W437G
mutation occurs in the middle of the 13th h-strand of the C-
terminal small subdomain, which is part of the Bh D
domain [6]. The introduction of the small glycine residue
in place of the much larger tryptophan, physiologically
involved in a strong interaction with the side chain of
L353, could perturb the Bh D-domain structure and result
in afibrinogenemia.
To confirm the predicted pathogenetic role of the W437G
mutation, qualitative and quantitative in vitro expression
analyses were performed. Wild-type and W437G mutant
fibrinogens were independently and transiently expressed in
COS-1 cells, a cell line widely used to study fibrinogen
assembly and secretion [14,16]. Pulse-chase experiments
showed normal synthesis but altered secretion of the hex-
americ mutant molecule. In particular, fibrinogen accumu-
lated intracellularly rather than being secreted (Fig. 3A and
B). These results, confirmed also by ELISA measurements
of fibrinogen content both inside and outside the transfected
cells (Fig. 4), confirmed the secretion defect caused by the
W437G mutation. Even though in culture media no mutant
fibrinogen was detectable by immunoprecipitation, the
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of small amounts of the mutant protein.
Typically, missense mutations affecting amino acids not
involved in catalytic or binding activities increase the
fraction of proteins present in non-functional conformations
and therefore susceptible to a rapid intracellular degradation
or to an intracellular aggregation [20]. Since the lack of one
fibrinogen chain is sufficient to abolish fibrinogen assembly
[16], the intracellular detection of the hexameric fibrinogen
molecules in cells expressing the W437G mutation (Fig. 3A,
middle) suggests that the mutant Bh-chain is sufficiently
stable to be assembled but the resulting hexameric molecule
is intracellularly retained (Fig. 3A, middle). Moreover,
normal synthesis and assembly of BhW437G fibrinogen
are suggested by the similar intensity of wild-type and
mutant hexameric fibrinogen bands obtained from cell
lysates after 2 h labelling (chase period 0) (Fig. 3A, right).
Some missense mutations, affecting acute phase proteins,
are known to cause endoplasmic reticulum storage diseases
(ERSDs), characterised by plasma deficiency and by hepatic
storage of the corresponding protein [21]. In particular, as
far as hypofibrinogenemia is concerned, two missense
mutations, each identified in the fibrinogen g-chain gene
in the heterozygous state, were demonstrated to cause ERSD
[22,23]. Hepatic storage caused by the W437G mutation, as
suggested by the intracellular retention of the in vitro
expressed mutant protein, might be verified by morpholog-
ical studies on liver specimens obtained from individuals
carrying the W437G mutation. Owing to obvious ethical
constraints, no liver biopsy material was available to eval-
uate the presence of fibrinogen inclusions, either from the
proband or from his relatives. Therefore, the question of
whether the patients have hepatic fibrinogen inclusion
bodies or other histologic signs of liver disease is left open.
Nonetheless, some degradation of the mutant molecules
may be hypothesised, considering that the intracellular
fibrinogen content measured 48 h after transfection in cells
expressing the W437G mutant fibrinogen was only moder-
ately increased (178% of the wild type, see Fig. 4).
Among Bh-chain missense mutations, besides the al-
ready known L353R and G400D and the here reported
W437G mutations all responsible for congenital afibrinoge-
nemia, only two additional missense mutations (R255H and
D316Y) have been described in the fibrinogen Bh-chain D
domain in the heterozygous state in two hypofibrinogene-
mic families [24,25]. Since the mutant R255H and D316Y
Bh-chains were not detected in circulating plasma fibrino-
gen of the corresponding patients [24,25], they probably
cause a secretion defect, as demonstrated for the L353R,
G400D, and W437G mutations.
The structural importance of the Bh-chain D domain in
fibrinogen assembly and secretion is further supported by
the recent identification of truncating mutations at residue
440 (W440X) [26] and at the very same codon of the here
reported mutation (W437X) [12]. The latter mutant Bh-
chain was expressed in combination with wild-type Aa- andg-chains demonstrating impaired secretion of the mutant
protein [12].
In conclusion, the elucidation of the pathogenetic role of
the W437G mutation increases the number of naturally
occurring missense mutations that result in afibrinogenemia
by impairing fibrinogen secretion. The identification of such
spontaneous mutants, besides broadening the mutational
spectrum of this rare coagulation disorder, can give insights
into the protein regions and residues crucial for fibrinogen
assembly and secretion.Acknowledgements
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